A Phase II Trial of Lanreotide for the Prevention of Postoperative Pancreatic Fistula
Status:
Active, not recruiting
Trial end date:
2021-04-01
Target enrollment:
Participant gender:
Summary
This is a single arm investigator-initiated study designed to test the feasibility and
potential efficacy of preoperative lanreotide to reduce the risk of postoperative abscess or
pancreatic leak and fistula. All consenting patients undergoing planned elective
pancreaticoduodenectomy or distal pancreatectomy for malignancy or suspected malignancy will
be treated with a single deep subcutaneous dose of lanreotide prior to planned resection on
the day of surgery. Following this intervention, care will be based on standard treatment
protocols. Sixty-day mortality and morbidity will be collected for all patients.